Vion Pharmaceuticals News (NASDAQ:VION)
| Latest Vion Pharmaceuticals News Headlines | | Date | Time | Source | | | 08/14/2008 | 4:30PM | PRNUS | Vion Pharmaceuticals is Delisted from Nasdaq Stock Market
NEW HAVEN, Conn., Aug. 14 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced that the Company had received a letter from NASDAQ on August 13, 2008 informing the Company that it would be delisted from the Nasdaq Stock Market and trading in its shares would be suspended effective the open... More...>> |
| 08/04/2008 | 5:00PM | PRNUS | Vion Reports 2008 Second Quarter and Six-Month Results
Quarterly Conference Call to be Held Thursday August 7 at 8:30 a.m.
NEW HAVEN, Conn., Aug. 4 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced financial results for the three-month and six-month periods ended June 30, 2008.
The Company reported a net loss of $7.9 million, or $1.06 per... More...>> |
| 06/13/2008 | 3:30AM | PRNUS | Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodyspla
NEW HAVEN, Conn., June 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced that data from a previously conducted Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS... More...>> |
| 06/02/2008 | 3:06PM | PRNUS | Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute M
NEW HAVEN, Conn., June 2 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced that interim data from the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with de novo poor-risk acute myelogenous leukemia (AML) had been presented at the 44th... More...>> |
| 06/02/2008 | 9:20AM | PRNUS | BeaconEquity.com Issues TraderNotes on Biotechnology Stocks: TPIM, RXII, VION, CUR, AMGN, GILD, BIIB, GENR
DALLAS, June 2 /PRNewswire/ -- BeaconEquity.com announces the availability of TraderNotes on stocks that are making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m
Today's TraderNotes include: TapImmune Inc. (OTC:TPIM) (BULLETIN BOARD: TPIM) , RXi Pharmaceuticals... More...>> |
| 06/02/2008 | 7:30AM | PRNUS | Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapse
NEW HAVEN, Conn., June 2 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced that data from the Phase III trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in patients with first relapse of acute myelogenous leukemia (AML) had been presented at... More...>> |
| 05/30/2008 | 8:00AM | PRNUS | Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
NEW HAVEN, Conn., May 30 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced that data from two clinical trials of its lead anticancer agent Cloretazine(R) (VNP40101M) in acute myelogenous leukemia (AML) would be presented in posters at the 2008 American Society of Clinical Oncology (ASCO(R... More...>> |
| 05/08/2008 | 8:00AM | PRNUS | Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced the start of an investigator-sponsored Phase I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in elderly patients with previously untreated acute myelogenous... More...>> |
| 05/08/2008 | 7:45AM | PRNUS | Vion Pharmaceuticals to Appeal Nasdaq Delisting
Company to Request Hearing with Listing Qualifications Panel
NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced that it had received a letter, dated May 7, 2008, from The Nasdaq Stock Market Inc. (Nasdaq) stating that the Company's common stock will be delisted... More...>> |
| 05/06/2008 | 8:00AM | PRNUS | Vion Pharmaceuticals to Host Conference Call to Discuss 2008 First Quarter Financial Results
NEW HAVEN, Conn., May 6 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced that it would hold a conference call on Thursday, May 8, 2008 to discuss its 2008 first quarter financial results. The call will begin at 8:30 a.m. Eastern Time.
To participate in the conference call, please dial... More...>> |
| 05/05/2008 | 4:30PM | PRNUS | Vion Reports 2008 First Quarter Results
NEW HAVEN, Conn., May 5 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced financial results for the three-month period ended March 31, 2008.
The Company reported a net loss of $8.2 million, or $1.14 per share, for the three-month period ended March 31, 2008, compared with a net loss... More...>> |
| 04/15/2008 | 4:30PM | PRNUS | Vion Pharmaceuticals Files Plan With Nasdaq
NEW HAVEN, Conn., April 15 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (NASDAQ:VION) today announced that it had filed a plan to achieve and sustain compliance with The Nasdaq Capital Market listing requirements, including the time frame for completion of the plan.
Previously, the Company announced that it... More...>> |
| 03/26/2008 | 8:00AM | PRNUS | Vion Pharmaceuticals Receives Nasdaq Notice
NEW HAVEN, Conn., March 26 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced that it received a letter, dated March 24, 2008, from The Nasdaq Stock Market, Inc., notifying the Company that it does not comply with Marketplace Rule 4310(c)(3) which requires the Company to have a minimum... More...>> |
| 02/20/2008 | 2:00PM | PRNUS | Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
NEW HAVEN, Conn., Feb. 20 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced that the Company would implement a one-for-ten reverse split of its common stock, effective at 5:00 p.m. Eastern Time on Wednesday, February 20, 2008.
On a pre-split basis, Vion Pharmaceuticals has 81,017,569... More...>> |
| 02/15/2008 | 5:31PM | PRNUS | Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
NEW HAVEN, Conn., Feb. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced that the Company had paid interest due February 15, 2008 on its 7.75% Convertible Senior Notes due 2012 (the "Notes"). The aggregate principal amount of the Notes is $60 million.
The Company paid $2,376,666.67... More...>> |
| 02/13/2008 | 4:15PM | PRNUS | Vion Pharmaceuticals Holds Special Meeting of Stockholders
Stockholders Approve Board Authority to Implement Reverse Stock Split and Reduce the Number of Total Shares and Authorized Shares
NEW HAVEN, Conn., Feb. 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) announced that a Special Meeting of Stockholders was held at the Omni Hotel in New Haven, Connecticut... More...>> |
| 02/04/2008 | 8:00AM | PRNUS | Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
NEW HAVEN, Conn., Feb. 4 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced that William Hahne, M.D. has joined the Company's senior management team as Vice President, Medical.
Alan Kessman, Chief Executive Officer, said, "We are extremely pleased to have Bill Hahne joining Vion in medical... More...>> |
| 01/08/2008 | 8:00AM | PRNUS | Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Rela
Company to Hold Conference Call at 10:30 A.M. Eastern Time Today
NEW HAVEN, Conn., Jan. 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on the Phase III trial (Vion Study CLI-037) of its lead anti-cancer... More...>> |
| 12/10/2007 | 7:30AM | PRNUS | Vion Pharmaceuticals Presents Preliminary Data from its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenou
NEW HAVEN, Conn., Dec. 10 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (NASDAQ:VION) today announced that data from its pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with de novo poor-risk acute myelogenous leukemia (AML) had been presented at the Annual Meeting... More...>> |
| 12/06/2007 | 8:00AM | PRNUS | Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Soc
Company to Hold Conference Call on Monday, December 10, 2007
NEW HAVEN, Conn., Dec. 6 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (NASDAQ:VION) today announced that preliminary data from its pivotal Phase II trial of Cloretazine(R) (VNP40101M) in elderly patients with de novo acute myelogenous leukemia (AML... More...>> |
|
|
|